

Express Mail Label No.: EL 946405752 US

Date of Deposit: August 19, 2002

DT05 Rec'd PCT/PTO 19 AUG 2002

Attorney Docket No. 14445-504 NATL.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chalifour *et al.*  
SERIAL NUMBER: 10/009,122 EXAMINER: Not Yet Assigned  
FILING DATE: June 18, 2002 ART UNIT 1614  
FOR: STEREOSELECTIVE ANTIFIBRILLOGENIC PEPTIDES AND PEPTIDOMIMETICS  
THEREOF

August 19, 2002  
Boston, Massachusetts

Office of Initial Patent Examination  
Filing Receipt Corrections  
Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

- ☒ Request for corrected filing receipt (2 pages);
- ☒ Copy of filing receipt marked with corrections (2 pages); and
- ☒ Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts. Applicants believe that no fee is due. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Ref. No. 14445-504 NATL. A duplicate copy of this transmittal letter is enclosed herewith.



30623

PATENT TRADEMARK OFFICE

Respectfully submitted,

Ivor R. Elrifi, Reg. No.: 39,529  
Barry J. Marenberg, Reg. No.: 40,715  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Date: August 19, 2002

RECEIVED

SEP 24 2002

TRA 1702711v1

TECH CENTER 1600/2900

Express Mail Label No.: EL 946405752 US  
Date of Deposit: August 19, 2002

Attorney Docket No. 14445-504 NATL.



**COPY**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Chalifour *et al.*  
SERIAL NUMBER: 10/009,122 EXAMINER: Not Yet Assigned  
FILING DATE: June 18, 2002 ART UNIT 1614  
FOR: STEREOSELECTIVE ANTIFIBRILLOGENIC PEPTIDES AND PEPTIDOMIMETICS  
THEREOF

August 19, 2002  
Boston, Massachusetts

Office of Initial Patent Examination  
Filing Receipt Corrections  
Commissioner for Patents  
Washington, D.C. 20231

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the above-referenced patent application are the following documents:

- ☒ Request for corrected filing receipt (2 pages);
- ☒ Copy of filing receipt marked with corrections (2 pages); and
- ☒ Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts. Applicants believe that no fee is due. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Ref. No. 14445-504 NATL. A duplicate copy of this transmittal letter is enclosed herewith.



30623

PATENT TRADEMARK OFFICE

Respectfully submitted,

Ivor R. Elrifi, Reg. No.: 39,529  
Barry J. Marenberg, Reg. No.: 40,713  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Date: August 19, 2002

TRA 1702711v1

**RECEIVED**

SEP 24 2002

TECH CENTER 1600/2900

#8

Express Mail Label No.: EL 946405752 US

Date of Deposit: August 19, 2002

Attorney Docket No. 14445-504 NATL.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chalifour *et al.*

SERIAL NUMBER: 10/009,122

EXAMINER: Not Yet Assigned

FILING DATE: June 18, 2002

ART UNIT 1614

FOR: STEREOSELECTIVE ANTIFIBRILLOGENIC PEPTIDES AND PEPTIDOMIMETICS  
THEREOF

August 19, 2002  
Boston, Massachusetts

Office of Initial Patent Examination  
Filing Receipt Corrections  
Commissioner for Patents  
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

1. Applicants request a Corrected Filing Receipt for the above-mentioned patent application. Applicants enclose a copy of the Filing Receipt with the corrections noted thereon. Issuance of a corrected filing receipt is respectfully requested.
2. There are errors with respect to the following data, which are:  
☒ incorrectly entered  
*and/or*  
☐ omitted.

- |    | <i>Error in</i>                                      | <i>Correct data</i> |
|----|--|---------------------|
| 1. | <input type="checkbox"/> Applicants' name            |                     |
| 2. | <input type="checkbox"/> Applicants' address         |                     |
| 3. | <input type="checkbox"/> Title                       |                     |
| 4. | <input type="checkbox"/> Filing Date                 |                     |
| 5. | <input type="checkbox"/> Serial Number               |                     |
| 6. | <input type="checkbox"/> Foreign/PCT Application Re: |                     |
| 7. | <input type="checkbox"/> Continuing Data             |                     |

RECEIVED  
SEP 24 2002  
TECH CENTER 1600/2900

8. ☒ Other:

Attorney Docket Number

Attorney Information

Delete: [14445-504]


Replace with: 14445-504 NATL.

Delete: [Michael Morency]

Replace with: Ivor R. Elrifi, Ph.D., Esq.

3. Applicants believe that no fee is due. However, the Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 14445-504 NATL.

Respectfully submitted,



Ivor R. Elrifi, Reg. No.: 39,529

Barry J. Matenberg, Reg. No.: 40,715

Attorneys for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241



AUG 19 2002

## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/009,122	06/18/2002	1614	1182	1445-504	7	29	2

1445-504 NATL.

CONFIRMATION NO. 5542

~~Michael Moroney~~ **Ivor R. Elrif, Ph.D., Esq.**  
Mintz Levin Cohn Ferris Glovsky & Popeo  
One Financial Center  
Boston, MA 02111

**RECEIVED**

FILING RECEIPT

AUG 15 2002



\*OC000000008570927\*

MINTZ LEVIN, BOSTON  
PATENT DOCKET DEPT.

Date Mailed: 08/08/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

**Applicant(s)**

Robert Chalifour, Quebec, CANADA;  
Francine Gervais, Quebec, CANADA;  
Ajay Gupta, Quebec, CANADA;

**Domestic Priority data as claimed by applicant**

THIS APPLICATION IS A 371 OF PCT/CA00/00515 05/04/2000

**Foreign Applications**

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

**Title**

Stereoselective antifibrillogenic peptides and peptidomimetics thereof

**Preliminary Class**

514

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).